WuXi AppTec earnings for the nine months ended September 30, 2026, showed revenue rising 38.6% to RMB 45.54 billion, prompting the pharmaceutical research and manufacturing services company to raise its full-year revenue and adjusted free cash flow forecasts. The October 26 announcement also showed faster profit growth and a larger continuing-operations backlog.
Key Takeaways
- Full-year revenue guidance increased to RMB 61.0–61.9 billion from RMB 58.5–60.5 billion.
- Adjusted non-IFRS net profit rose 74.4%, outpacing revenue growth as margins widened.
- Management raised its cash flow forecast while increasing the lower end of planned capital spending.
Table of Contents
- WuXi AppTec earnings show stronger margins
- Higher guidance follows growth in customer work
- Cash generation supports expanded capacity plans
- Conclusion
WuXi AppTec earnings show stronger margins
Revenue from continuing operations grew 46.3% year over year, faster than the 38.6% increase in total revenue. That scope includes WuXi Chemistry, WuXi Testing, WuXi Biology and Others, with historical figures adjusted accordingly.
The company’s first-three-quarter results announcement showed adjusted non-IFRS net profit reaching RMB 18.38 billion, up 74.4%. Its adjusted net profit margin widened by 8.3 percentage points to 40.4%, while adjusted gross margin rose 7.7 percentage points to 54.8%. Profit therefore grew substantially faster than sales.
Adjusted non-IFRS diluted earnings per share increased 68.8% to RMB 6.21. Separately, net profit attributable to shareholders under China Accounting Standards rose 60.6% to RMB 19.40 billion, with diluted earnings per share increasing 55.6% to RMB 6.55.
These measures use different accounting bases. WuXi AppTec cautioned that adjusted non-IFRS figures supplement, rather than replace, accounting results. The third-quarter report was unaudited.
| Item | Details |
|---|---|
| 2026 revenue guidance midpoint | RMB 61.45 billion, versus RMB 59.50 billion previously. |
| 2026 adjusted free cash flow midpoint | RMB 15.0 billion, versus RMB 14.0 billion previously. |
| 2026 capital expenditure midpoint | RMB 8.25 billion, versus RMB 8.0 billion previously. |
| Cash dividends distributed in January–September | RMB 6.22 billion, including RMB 4.71 billion for the 2025 annual dividend and RMB 1.51 billion for the 2026 interim dividend. |
Higher guidance follows growth in customer work
Management now expects continuing-operations revenue to grow 40%–42% in 2026, compared with its previous forecast of 35%–39%. The revised total revenue range lifts the midpoint by RMB 1.95 billion, to RMB 61.45 billion.
Chairman and Chief Executive Officer Ge Li attributed the performance to the greater success of multiple customers’ products, the company’s integrated contract research, development and manufacturing model, and its global team. Continuing-operations backlog reached RMB 76.74 billion at September 30, up 36.4% from a year earlier.
The backlog provides visibility into future work, but it is not revenue already earned. The full-year targets likewise remain management forecasts rather than completed results. WuXi AppTec said it was confident of maintaining a stable and resilient adjusted non-IFRS net profit margin for 2026, without giving a numerical full-year margin target.
Cash generation supports expanded capacity plans
Adjusted operating cash flow increased 58.9% to RMB 17.28 billion in the first nine months. Management raised its full-year adjusted free cash flow forecast to RMB 14.5–15.5 billion from RMB 13.5–14.5 billion, citing business growth and efficiency improvements.
The higher cash flow target comes alongside additional planned investment. WuXi AppTec adjusted its 2026 capital expenditure forecast to RMB 8.0–8.5 billion from RMB 7.5–8.5 billion to support accelerated global capacity development, including initiation of a new Changzhou site ahead of schedule.
The change raises the spending forecast’s lower bound while leaving its upper bound unchanged. It indicates that management expects stronger cash generation even as it commits to a higher minimum level of capacity investment.
Conclusion
WuXi AppTec earnings combined faster sales growth with wider margins and stronger cash generation. The next test is delivery against the raised 2026 revenue and adjusted free cash flow ranges while the company advances its expanded capacity plans.
Read More News
Disclaimer
This FinanceVelix article provides general information, not personalized financial, investment, legal, or tax advice. Market prices, interest rates and economic conditions can change; investments carry a risk of loss. Facts reflect the material available when published and may change. Check important information independently and consult a qualified professional when needed. Mentioning an asset, company, or service is not an endorsement.
